Introduction 1
The calcium-sensing receptor (CaSR), encoded by the CASR gene on chromosome 3q21.1, is a 2 1078 amino acid family C G protein-coupled receptor (GPCR) that is highly expressed in 3 calcitropic tissues including the parathyroid glands and kidneys, where it regulates serum Ca 2+ 4 concentrations by influencing parathyroid hormone (PTH) secretion and renal Ca 2+ excretion. 1 
5
The CaSR represents a major determinant of extracellular Ca 2+ homeostasis, and a haplotype 6 block containing a cluster of 3 polymorphisms which localize to the intracellular carboxyl terminus 7 (Ala986Ser, Arg990Gly, and Glu1011Gln) has been shown to contribute to the variance in serum 8
Ca 2+ in the general population, and to influence urinary Ca 2+ excretion. 2, 3 The Ala986Ser SNP has 9 been linked to higher serum calcium concentrations in the normal range by Genome-Wide 10 Association Studies (GWAS).
2
In contrast, the Arg990Gly SNP has a mild gain-of-function 11 phenotype 4 linked to lower serum calcium concentrations in the normal range, higher sensitivity 12 to the calcimimetic drug cinacalcet (Sensipar™) 5 , and elevated urinary Ca 2+ and nephrolithiasis 13 in some, but not all studies. 6 
14
The CaSR is also expressed in non-calcitropic tissues including heart and arterial vessels 7 , and 15 has been implicated in the pathogenesis of cardiovascular disease (CVD). The common CASR 16 SNP Ala986Ser has been associated with an increased prevalence of coronary artery disease 17 (CAD), myocardial infarction (MI) and all-cause cardiovascular mortality in hospitalized patients 18 who had undergone coronary angiography. 8 However, it is unclear whether the CaSR may 19 influence CVD risk through direct effects on the heart and arterial vessels or by indirectly altering 20 serum Ca 2+ concentrations. Indeed, serum Ca 2+ represents a CVD risk factor and calcium 21 supplements, which increase serum Ca 2+ concentrations, have been independently associated 22 with CVD risk, cardiovascular and all-cause mortality. 9, 10 Moreover, a large-scale Mendelian 23 randomization study found that SNPs in Ca 2+ -regulating genes were significantly associated with 24 both increased serum Ca 2+ concentrations and CAD; however whilst the CASR Ala986Ser SNP 25 had the greatest influence on serum Ca 2+ concentrations, it was not significantly associated with 1
CAD.
11 It thus remains to be established whether the cardiovascular effects of serum Ca 2+ are 2 mediated by, occur independently of or in conjunction with common CASR variants. Furthermore, 3 association studies characterizing the influence of CASR variants and serum Ca 2+ on calcitropic 4 and non-calcitropic disorders have been hampered by small samples sizes, and meta-analyses 5 are limited by the use of data from heterogeneous populations. To overcome these difficulties, we 6 utilized clinical, biochemical and whole exome sequences from a single patient cohort comprising 7 51,289 individuals derived from a stable US population of European origin. We assessed the 8 independent contributions of serum Ca 2+ and CASR common variants to cardiovascular diseases 9 including CAD. 10
Methods 11

DiscovEHR PATIENT COHORT 12
The cohort consisted of 51,289 patients with a median age of 61 years (interquartile range 48-72 13 years) (Table S1) , from the Geisinger Health System (GHS) who consented to participate in the 14
MyCode Community Health Initiative
12
, and whose germ-line DNA underwent whole exome 15 sequencing (DiscovEHR). 13 
16
CLINICAL DATA 17
The medians and means of all available serum biochemical and clinical parameters were 18 extracted from the electronic health record (EHR) in a de-identified manner. Patients studied had 19 a median value of 14 years of EHR data (Table S1) 
23
(mg/dL) + 0.8*(4-serum albumin (mg/dL)). Unique International Classification of Disease-9 (ICD9) 24 codes for each de-identified patient were obtained from an approved data broker in accordance 1 with Institutional Review Board approvals. 2
EXOME SEQUENCING 3
Sample preparation, exome sequencing, sequence alignment, variant identification, genotype 4 assignment and quality control steps (allele balance < 0.7, high quality combined allele read 5 depth (AD) of ≥ 8 reads, and per sample genotype quality (GQ) of ≥ 30) have been previously 6 described. 13 
7
ASSOCIATION STUDIES 8
ICD9 codes that were recorded for a minimum of 200 patients (3 or more independent encounters 9 per patient) were grouped into Phenome-Wide Association Study (PheWAS) codes 10 (Phecodes). 14, 15 showed significant associations at the CASR locus ( Figure S1 ). As previously reported 8 , the 3 strongest positive association was with the Ala986Ser (rs1801725) CASR SNP (p=1.6E-70; 4 beta=0.07255), whilst a negative association was identified for Arg990Gly (rs1042636) (p=5.75E-5 15; beta=-0.0442) ( Figure S1 ). The CaSR carboxyl terminus contains a cluster of SNPs 6 (Ala986Ser, Arg990Gly and Glu1011Gln) in a haplotype block that has been associated with 7 Ala986Ser SNP was 6.3%, and by the Arg990Gly SNP was 5.4% (controlling for age, sex, and 13 BMI). None of the haplotypes were significantly associated with serum phosphate or PTH 14 concentrations (Table 1 ; statistical analysis in Supplemental Table 2) . 15
Association of Common CASR Variants with Major Disease Phenotypes 16
A phenome-wide association study (PheWAS) using EHR-derived phenotypes [14] [15] [16] identified 17 significant disease associations for patients heterozygous (n=7,691) or homozygous (n=721) for 18
hyperparathyroidism, and disorders of mineral metabolism ( Figure 1A , Table 2 ). Both the 20
Ala986Ser and Arg990Gly SNPs were associated with CVD and the strongest associations for 21 the Ala986Ser SNP include an increased risk of peripheral circulatory disorders and paroxysmal 22 ventricular tachycardia ( Figure 1A , Table 2 ), while the strongest associations for the Arg990Gly 23 SNP showed a reduced risk of chronic ischemic heart disease, unstable angina and myocardial 24 infarction ( Figure 1B , Table 2 ). 25
Serum Ca 2+ and CASR Variants Modulate Coronary Artery Disease Risk 1
Associations of the common CASR SNPs Ser986 and Gly990 with a range of cardiovascular 2 disease ICD9 codes prompted an in-depth analysis of their respective impacts on CAD, a well-3 defined clinical phenotype. CAD patients were defined by an EHR history of coronary 4 revascularization, or history of acute coronary syndrome, ischemic heart disease or exertional 5 angina (ICD9 codes 410*-414*) with angiographic evidence of obstructive CAD (>50% stenosis 6 in at least one major epicardial vessel as determined by catheterization). 13, 18 Controls were 7 individuals without any case criteria or any single encounter or problem list diagnosis code 8 indicating CAD. 9
We first used LMEHR serum Ca 2+ alb ranges as a categorical variable to determine the relative CAD 10 risks of the CASR SNPs Ser986 and Gly990 relative to individuals having all reference alleles 11 (WT=Ala986/Arg990/Glu1011). CAD cases were sorted by LMEHR serum Ca 2+ alb range and 12 genotype, and plotted over the range of LMEHR serum Ca C.I. 0.66-0.98; p=0.034). CAD risks increased with LMEHR serum Ca 2+ alb range for Gly990 (8.5-17 9.0 mg/dL vs 9.5-10 mg/dL, O.R. = 1.53, C.I. 1.14-2.06; p=0.0053) and WT (8.5-9.0 mg/dL vs 9.5-18 10 mg/dL, O.R. = 1.3, C.I. 1.13-1.5, p=0.0003). When analyses were corrected for the well-19 established CAD risk factors of age, sex, and BMI, the Gly990 genotype was shown to be an 20 independent factor which significantly decreased the risk of CAD when LMEHR serum Ca 2+ alb is in 21 the 8.5-9.0 mg/dL range ( Figure 2B) . 22
We next determined whether CAD risks are modified in the context of the carboxyl terminal 23 haplotype ( Figure 2C ). In this case, one or two Ser986 alleles for patients in the 8. 5-9.0 Figure 2C ). CAD risk was also higher 3 for the Ser986 relative to the Gly990 allele in the serum Ca 2+ alb range from 9.0-9.5 mg/dL (O.R. = 4 1.23, C.I. 1.05-1.45, p=0.0103) ( Figure 2C ). When compared with the WT haplotype, those 5 having the Gly990 allele had a reduced CAD risk in the 8.5-9.0 mg/dL serum Ca 2+ alb range (O.R. 6 = 0.805, C.I. 0.66-0.98, p=0.034). CAD risk for patients having median serum Ca 2+ alb levels above 7 9.5 mg/dL was independent of genotype ( Figure 2C) . We corrected the analysis of haplotype 8 associated CAD risks for age, sex and BMI ( Figure 2D ), and results again demonstrated the 9 importance of the Gly990 allele as an independent determinant of reduced CAD risk. CaSR is highly expressed in the pancreatic islets and kidneys. [19] [20] [21] We therefore determined 18 whether the Ser986 or Gly990 CASR SNPs influenced CAD risk through differential effects on 19 the prevalence of type 2 diabetes (T2D) or chronic kidney disease (CKD). Individuals 20 homozygous for the Ser986 SNP had a small but significant increase in the prevalence of T2D in 21 the 51,289 individual DiscovEHR cohort ( Figure S2D ), but the CASR SNPs had no differential 22 effects on other cardio-metabolic risk factors, including dyslipidemia ICD9 calls or blood pressure 23 (Figures S2ABC), glycemia (hemoglobin A1c concentrations, Figure S2E ), estimated glomerular 24 filtration rate ( Figure S2F ) or serum lipids ( Figure S3 ). It should be noted that drug treatments for 25 diabetes and/or dyslipidemia may obscure the full effect of the CaSR variants on these measures. 1
Individuals homozygous for the Gly990 SNP in the background of the reference alleles at both of 2 the other common SNPs in the haplotype had a significantly reduced prevalence of CKD (stages 3 4 (ICD9 code 585.4) + 5 (585.5) + unspecified (585.9), but excluding end stage renal disease 4 (585.6), Figure 3A) , which was reflected in significantly lower serum creatinine levels ( Figure 3B) . 5
Overall, results suggest that CASR common variants modify the effect of serum Ca 2+ on CAD, 6 either directly and/or by effects in the kidney. 7
Discussion 8
The availability of whole exome sequencing coupled with phenotype-rich electronic health record 9 data has provided a unique opportunity to define cardiovascular and other disease associations 10 for common CASR variants, and dissect the contribution of serum Ca 2+ to CAD risk. Therefore, the CASR tri-locus haplotype 21 (Ala986Ser/Arg990Gly/Glu1011Gln) should be used to assess disease risks, as the interaction(s) 22 of risk and protective alleles both need to be taken into account. When considered alone, the 23 CASR carboxyl terminal Ser986 SNP significantly increased CAD risk, confirming a previous 24 study 8 , whilst the Gly990 SNP significantly reduced this risk. These opposing effects of the CaSR 25 SNPs on CAD risk occurred at serum Ca 2+ concentrations in the range between 8.5-9.5 mg/dL, 1 which accounts for the majority (83%) of patients in the CAD analysis. When considered within 2 the tri-locus haplotype, the reduced risk conferred by the Arg990Gly SNP remained significant. 3
Of note, the frequency of the Arg990Gly SNP varies among ethnicities (1000Genomes), and may 4 contribute to observed differential risks of CAD in different populations. The finding that these 5 associations of the CASR SNPs with CAD occurred independently of cardio-metabolic risk factors 6 such as blood pressure, serum lipids or hemoglobin A1c concentrations, highlights a potential 7 role for CaSR expressed in the cardiovascular system in the pathogenesis of CAD. Indeed, the 8 CaSR is expressed in the aorta and coronary arteries 23 , and abnormal function of the arterial 9
CaSR has been implicated the pathogenesis of vascular calcification. 24 Moreover, we have shown 10 that the homozygous Gly990 CaSR SNP is associated with a significant reduction in CKD cases. 11
The relevance of this finding to the pathophysiology of CKD is uncertain, however, it is notable 12 that studies involving rats have shown CaSR to protect against glomerular disease.
25 Moreover, 13 as CKD represents a major cardiovascular risk factor, the reduction in CKD may in part explain 14 why the Gly990 CaSR SNP is associated with a reduced risk of CAD. Furthermore, the Ser986 15 CaSR SNP is associated with an increase in cases of type 2 diabetes, and these findings are in 16 keeping with a reported study involving renal transplant recipients, which showed the Ser986 SNP 17 to be associated with increased serum glucose concentrations. 26 
18
The approaches used in this study have notable benefits and a few limitations. Combining WES 19 and quantitative clinical measures from a single large healthcare system allowed unequivocal 20 definitions of cases and controls, improving the power to discern associations. Another benefit is 21 the ability to study a broad range of clinical conditions in an unbiased manner. The de-identified 22 nature of the data confers some limitations, including a lack of specialized clinical data and/or 23 testing to support particular diagnoses, compounded by the inability to call back patients for 24 additional phenotyping. These limitations promoted a focus on the CAD phenotype, which was12 validated by angiographic evidence of obstructive CAD 13, 18 . Finally, we did not explicitly address 1 whether patients were on supplemental calcium ± vitamin D, which may influence serum Ca 2+ 2 concentrations, but rather focused on outpatient EHR-based median Ca 2+ alb levels to assess CAD 3 risks. The large numbers of patients and extensive clinical measures did, however, allowed for 4 statistically significant findings, and the present results argue for the importance of including 5 CASR haplotypes in re-analyses of renal failure studies that use cinacalcet. Finally, large 6 independent cohorts combining WES and granular EHR data are currently unavailable for 7 replication of the observed associations. As other population sequencing efforts such as the UK 8
Biobank and the National Institutes of Health Precision Health Initiative (All of Us) come to fruition, 9 we expect replication to be possible. The present study can also be followed-up with an in-depth 10 prospective study with specifically recruited patients who can undergo more rigorous testing. 11
In conclusion, common CASR SNPs within the carboxyl terminal tri-locus haplotype are 12 significantly associated serum Ca 2+ and with cardiovascular diseases, and modify the effects of 13 serum calcium on CAD risk, independently of other risk factors. 14
Acknowledgements 15
We thank the Phenotype Core at Geisinger for providing de-identified clinical data, and the 16 patients who contributed to MyCode to make these studies possible. We thank Dr. Janet Table 2 . B. PheWAS 17 results for the Arg990Gly SNP, as described in A. All results at p < 0.01 in Table 2 . 18 
